SORRENTO THERAPEUTICS WKN: A1W8DY ISIN: US83587F2020 Kürzel: SRNE Forum: Aktien Thema: Hauptdiskussion
Sorrento Therapeutics, Inc. (NASDAQ:SRNE) is a San Diego, California-based biotech company developing treatments for cancer, intractable pain, and COVID-19. The company has eight manufacturing sites, five in the US and three in China. ADVERTISEMENT In a research note issued to investors on November 2, Brandon Folkes at Cantor Fitzgerald started coverage on Sorrento Therapeutics, Inc. (NASDAQ:SRNE) with a target price of $5 and assigned the stock an Overweight rating. The target price reflects a handsome upside potential of 284% from the closing price as of December 7. In August, the drug candidate SP-103 from Scilex, Sorrento Therapeutics, Inc.'s (NASDAQ:SRNE) majority-owned subsidiary, was given fast-track status by the U.S. Food and Drug Administration (FDA). The drug is targeted toward the treatment of severe low back pain (LBP). Folkes believes that Sorrento Therapeutics, Inc. (NASDAQ:SRNE) has the ability to develop multiple best-in-class products in high-value fields of oncology, non-opioid pain relief, and infectious diseases like COVID-19. Experts think Sorrento Therapeutics, Inc. (NASDAQ:SRNE) is trading at a significant valuation discount compared to its rivals, making it one of the best small-cap stocks to invest in.
Sorrento Therapeutics, Inc. (NASDAQ:SRNE) is a San Diego, California-based biotech company developing treatments for cancer, intractable pain, and COVID-19. The company has eight manufacturing sites, five in the US and three in China. ADVERTISEMENT In a research note issued to investors on November 2, Brandon Folkes at Cantor Fitzgerald started coverage on Sorrento Therapeutics, Inc. (NASDAQ:SRNE) with a target price of $5 and assigned the stock an Overweight rating. The target price reflects a handsome upside potential of 284% from the closing price as of December 7. In August, the drug candidate SP-103 from Scilex, Sorrento Therapeutics, Inc.'s (NASDAQ:SRNE) majority-owned subsidiary, was given fast-track status by the U.S. Food and Drug Administration (FDA). The drug is targeted toward the treatment of severe low back pain (LBP). Folkes believes that Sorrento Therapeutics, Inc. (NASDAQ:SRNE) has the ability to develop multiple best-in-class products in high-value fields of oncology, non-opioid pain relief, and infectious diseases like COVID-19. Experts think Sorrento Therapeutics, Inc. (NASDAQ:SRNE) is trading at a significant valuation discount compared to its rivals, making it one of the best small-cap stocks to invest in.
Mehr zu diesem Wert
|
|
Thema | ||
|---|---|---|---|
| 1 | SORRENTO THERAPEUTICS Hauptdiskussion | ||
| 2 | SORRENTO INFORMATIV | ||
| 3 | Sorrento, Spam frei!! | ||
| 4 | Ausschließlich Sorrento News | ||
| 5 | Never Surrender ✌️ |
|
|
Thema | ||
|---|---|---|---|
| 1 | NVIDIA Hauptdiskussion | -1,09 % | |
| 2 | MicroStrategy | +12,06 % | |
| 3 | BAYER Hauptdiskussion | -3,26 % | |
| 4 | für alle, die es ehrlich meinen beim Traden. | ||
| 5 | Trading- und Aktien-Chat | ||
| 6 | Super Micro Computer Hauptdiskussion | -5,98 % | |
| 7 | GAMESTOP Hauptdiskussion | +4,40 % | |
| 8 | MICROSTRATEGY Hauptdiskussion | +12,06 % | |
| 9 | PAG911 | -4,80 % | |
| 10 | Marathon Digital Holdings | +11,82 % | Alle Diskussionen |
|
|
Thema | ||
|---|---|---|---|
| 1 | NVIDIA Hauptdiskussion | -1,14 % | |
| 2 | MicroStrategy | +11,91 % | |
| 3 | BAYER Hauptdiskussion | -3,36 % | |
| 4 | Super Micro Computer Hauptdiskussion | -6,37 % | |
| 5 | GAMESTOP Hauptdiskussion | +3,94 % | |
| 6 | PAG911 | -4,77 % | |
| 7 | MICROSTRATEGY Hauptdiskussion | +11,91 % | |
| 8 | Marathon Digital Holdings | +11,39 % | |
| 9 | Phunware Hauptdiskussion | +7,50 % | |
| 10 | PLUG POWER Hauptdiskussion | +0,53 % | Alle Diskussionen |